CannTrust (OTCMKTS:CNTTF) & Eliem Therapeutics (NASDAQ:ELYM) Financial Review

Insider and Institutional Ownership

0.1% of CannTrust shares are held by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares CannTrust and Eliem Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CannTrust	N/A	N/A	N/A
Eliem Therapeutics	N/A	-47.03%	-45.97%

Volatility and Risk

CannTrust has a beta of 4.52, meaning that its share price is 352% more volatile than the S&P 500. Comparatively, Eliem Therapeutics has a beta of -0.39, meaning that its share price is 139% less volatile than the S&P 500.

Valuation and Earnings

This table compares CannTrust and Eliem Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CannTrust	$15.96 million	0.00	$7.39 million	$0.07	N/A
Eliem Therapeutics	N/A	N/A	-$35.12 million	($0.53)	-16.81

CannTrust has higher revenue and earnings than Eliem Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than CannTrust, indicating that it is currently the more affordable of the two stocks.

Summary

CannTrust beats Eliem Therapeutics on 7 of the 9 factors compared between the two stocks.

About CannTrust

CannTrust Holdings Inc. produces and distributes pharmaceutical grade medical cannabis products in Canada. It sells dried cannabis and oil extractions to the client based on the medication document provided by health care practitioner. The company has a partnership with Gold Coast University Hospital. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.

About Eliem Therapeutics

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.